Linked Life Data

11370541

Source:http://linkedlifedata.com/resource/pubmed/id/11370541

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-5-23
pubmed:abstractText
Thyroid carcinoma is the most frequent endocrine malignant neoplasm even if a rare occurrence (0.5%-1.0%) of all human malignant tumors. Primary differentiated (papillary and follicular) forms represent over 90% of the total. Since recurrence of thyroid carcinoma can occur even after several years, patients must undergo a life-long follow-up. Thyroglobulin, being organ-specific, plays a major role as tumor marker and it is used essentially in the monitoring and follow-up of patients with differentiated thyroid carcinoma, both during L-thyroxine suppressive therapy and when it is discontinued or after recombinant TSH administration. The presence of antithyroglobulin antibodies masks the real value of thyroglobulin and therefore, at the same time, antithyroglobulin antibodies should always be determined.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0390-7740
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
239-44
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:articleTitle
Clinical and laboratory follow-up in differentiated thyroid carcinoma.
pubmed:affiliation
Istituto di Medicina Nucleare, Università Cattolica del S. Cuore, Policlinico A. Gemelli, Roma.
pubmed:publicationType
Journal Article, Review